https://www.selleckchem.com/pr....oducts/epacadostat-i
The SARAH (Sorafenib Versus Radioembolization inAdvanced Hepatocellular Carcinoma) trial (ClinicalTrials.gov Identifier NCT01482442) did not show a significant survival benefit for patients treated with transarterial radioembolization (TARE) compared with continuous oral sorafenib. The improved toxicity profile of patients treated with TARE in the trial, however, could result in a quality of life benefit in economic evaluations. Our objective was to perform a cost-utility analysis of TARE versus sorafenib for locally adva
Curtir
Comentario
Compartilhar
